Objectives. The Liquemin in Myocardial Infarction During Thrombolysis With Saruplase (LIMITS) study was instituted ta evaluate and characterize the effect of a prcthrombolytic heparin bolus (5,000 IU) on the efficacy and safety of saruplase in patients with acute myocardial infarction.
Objectives. The Liquemin in Myocardial Infarction During
Thrombolysis With Saruplase (LIMITS) study was instituted ta evaluate and characterize the effect of a prcthrombolytic heparin bolus (5,000 IU) on the efficacy and safety of saruplase in patients with acute myocardial infarction.
Background. Heparin has been used after thrombolytie therapy for acute myocardial infarction to prevent reocclusion of the infarct.related artery.
Methods. The study was designed as a randomized, parallelgroup, double-blind, mnlticenter trial. Patients were treated within 6 h of onset of symptoms with either a bolus of 5,000 IU of heparin (Liquemin) (n = 56, HSH group) or placebo (n = 62, PSH group) before thrombolytic treatment with saruplase given as a 20.rag bolus fol!owed by an infusion of 60 mg over 60 rain. Thirty minutes after completion of thrombolysis, an intravenous heparin infusion was administered for 5 days. Before coronary angiography was performed at 6 to 12 h after start of lysis, an additional bolus of 5,000 IU heparin was given to all patients. End points studied were patency of the infarct-related artery, changes in the hemostatic system and bleeding complications.
Results. In the HSH group (heparin-saruplase-heparin), 78.6% of patients had an open infarct-related vessel (Thrombolysis in Myocardial Infarction [TIMI] flow grade 2 or 3) compared with 56.5% in the PSH group (placebo-saruplase--heparin) (intention-to-treat analysis, p = 0.01). No significant difference was observed between the two groups with regard to changes in fibrinogen and fibrin/fibrinogen degradation products. A total of eight bleeding complications (14.3%) were observed in the HSH group and five (8.1%) in the PSH group; no cerebrovascnlar event occurred, and no allergic reaction was reported. A total of 12 patients died during the hospital stay, 3 in the HSH group (5.4%) and 9 in the P~tl group (14.5%).
Conclusions. In acute myocardial infarction, the administra. tion of a heparin bolus before thrombolytic therapy with saruplase is associated with a significantly higher patency at angiography 6 to 12 h after the start of thrombolysis without any appreciable increase in risk of bleeding.
(J Am CoU Cardio11995; 2&365-73) Heparin has been used empirically after thrombolytic therapy for acute myocardial infarction to prevent thrombotic reocclusion of the infarct-related coronary artery. The optimal strategy of heparin administration has not yet been determined. (Fig. 1 ). In the current randomized, double-blind trial, an intravenous bolus of heparin or placebo was given immediately before thrombolysis with saruplase. Thirty minutes after the saruplase infusion was completed a continuous intravenous infusion of heparin was administered to all patients for 5 days and was titrated to maintain thrombin time at two to three times the control value. The trial was designed to evaluate the effect of adjunctive heparin on coronary patency, incidence of bleeding complications and hemostasis after saruplase therapy in patients with acute myocardial infarction.
Ilg) Figure 1 . Schematic presentation of amino acid sequence of saruplase, single-letter code. Asterisks = active-site amino acids; arrows = cleavage sites into active high molecular weight two-chain uroldnasetype plasminogen activator der/vative (Lys 158) and low molecular weight derivative (Lys 135),
IS

Methods
The study was a randomized placebo-controlled, parallelgroup, double-blind trial. Fifteen local hospitals in proximity to the University Clinic of GOttingen, Germany, participated in the trial. The study protocol was. approved by the ethics committee of the University of Gfttingen as well as a central ethics and advisory board, which was specially convened for the study. All patients gave informed consent before entry into the study. The administration of trial medication was taken as the irrevocable entry of a patient into the study.
Inclusion criteria. Patients 20 to 75 years old with suspected acute myocardial infarction characterized by chest pain lasting for at least 30 rain despite oral treatmerit with nitrates or calcium antagonists, or both, were screened for entry. ST segment elevation of 0.3 mV in at least two precordial leads or ST segment elevation of 0.2 mV in at least two limb leads, or both, had to be present. Patients with a first or a previous infarction in a remote area were included. The interval between onset of symptoms and start of infusion was not to exceed 6 h.
Exclusion criteria. The currently accepted contraindications for thrombolytic therapy were used as exclusion criteria. In addition, patients who refused consent for coronary angiography, were obese or had cachexia (Broca index <70 or >130), administration of heparin in the previous 24 h, anticoagulation, cardiogenic shock, traumatic resuscitation, complete !eft bundle branch block, a cardiac pacemaker, previous coronary artery bypass surgery, endocarditis, acute pericarditis or atrial fibrillation of any origin were excluded.
Study treatment. Unless contraindicated all patients were started on a nitroglycerin (3 mg/h) infusion, which was titrated according to blood pressure and continued until oral nitrates could be given. One group of patients received a single intravenous bolus of 5,000 IU of heparin as premedication in blinded manner (heparin-saruplase-heparin [HSH] group). The second group of patients was given a corresponding placebo bolus (placebo--saruplase-heparin [PSH] group) (Fig.  2) . Thereafter, all patients immediately received a bolus of 20 mg of saruplase, followed by an intravenous infusion of 60 mg of saruplase over 60 min. An intravenous infusion of heparin (15 IU/kg per h) was started in all patients 30 min after completing the saruplase infusion and continued until the end of the fifth day after thrombolytic treatment. An additional Coronary angiography. After completion of the thrombolyric infusion patients were transferred from local hospitals to the catheterization laborato~j in G6ttingen so that coronary angiography could be performed between 6 and 12 h after the start of thrombolytic therapy. Standard projections were used, and each main coronary artery was viewed three times. Biplane ventriculography was also performed. Additional procedures, such as percutaneous transluminal coronary angioplasty or intracoronary lysis, were not allowed before visualization of the infarct-related artery. Qualitative assessment of the flow in the infarct-related artery was performed according to the TIMI grading system (16). The films were read by investigators who had no knowledge of the treatment: TIMI flow grades 2 and 3 were considered patent and 0 and 1 occluded. An estimation of the degree of stenosis of the infarct-related artery was recorded.
Hematologic studies. Blood was sampled through an indwelling needle used exclusively for this purpose. Blood samples were taken on admission and 60 rain after starting the study medication. A special kit was provided to ensure uniform handling of samples. The first 2 ml of blood was discarded. After coUection of the second sample, both samples were centrifuged, and the plasma was frozen. The concentrations of fibrinogen, fibrinogen degradation products, fibrin degradation products and thrombiu-antithrombin III complex were assayed centrally. Routine laboratory variables were documented at admission and on the following day.
Determination of infarct-specific enzyme activity, Venous blood samples were taken b~fore commencing thrombolytic therapy. Starting 60 rain after the end of the sarup~ase infusion, eight samples were to be taken at 2-h intervals up to 16 h, and a further eight samples were to be taken at 4-h intervals up to 48 h. The samples were sent to the University Hospital of GOttingen for central assay of the actMty of creatine kinase-MB isoenzyme (CK-MB).
Adverse events, electrocardiography and follow-up. Adverse events were reported as "bleeding complications" or "cardiovascular events" or "other adverse events." The severity of the event was evaluated using predefined criteria. The time and date of onset and duration, as well as the treatment required, were documented. Where possible, computerassisted tomography was performed to confiz~ the diagnosis if intracranial bleeding was suspected. All cardiac-related adverse events were to be reported. Specific questions were asked about the occurrence of angina w~thout remfarct~on, "angina, presumably reinfarction" and "confirmed reinfarction." Standard 12-lead electrocardiograms (ECGs) were recorded on admission and immediately before coronary angiography. A central analysis of inclusion ECGs was performed to confirm adherence to ECG inclusion criteria. Follow-up examinations took place at 3, 6 and 12 months. At all three follow-up visits the patients' functional state was classified according to the New York Heart Association functional score for heart failure and Canadian Cardiovascular Society score for angina pectoris, both ranging from I to IV. The ECGs were recorded at each visit. Reinfarctions and deaths were documented.
Statistical analysis, Because the study was designed as a pilot trial, no testable hypothesis was formulated. The patency of the infarct-related coronary artery, frequency of bleeding events and effects on hemostatic variables were analyzed as equivalent end points. Two hundred patients were considered sufficient to detect a difference in patency rates of 65% versus 82% (alpha 0.05, beta 0.2). The two groups of patients studied differed only in the prelysis administration of a heparin, or placebo to heparin, bolus. To detect poor efficacy (low patency rate) in the PSH group as early as posgible, a sequential analysis of the patency r~.tes, using discordant pairs, formed within each center, of patients from the two treatment groups was employed. This sequential analysis was based ou the study of subsequent pairs of patients on different treatments within each center with only pairs discordant concerning patency being used. An interim analysis was scheduled midway through the study. For this analysis, patency rates were compared by the Fisher exact test (alpha 0.05, two-sided). All data were collected and analyzed centrally. An intensive query system was used for missing or inconsistent data. Documentation and study monitoring were performed according to good clinical practice standards. The categoric variables are reported as percentage rates; mean values and standard deviations are used to describe continuous variables. Differences between treatment groups are reported by 95% confidence intervals (CIs).
Results
Interim analysis. After inclusion of the first 100 patients (March 1990) the results of the interim analysis were presented to the central ethics and advisory board. On the basis of this report the central ethics and advisory board decided on July 25, 1990 to terminate the study. By this time a total of 118 patients had been included in the trial, the results of which are presented in the present report.
Baseline characteristics and protocol compliance. Between March 19, 1989 and June 30, 1990~ 118 patients were enrolled in the study (56 in the HSH group, and 62 in the PSH group). The two groups of patients were similar with respect to age, gender, height, weight, site of infarction and heart rate ( Table 1) . A difference of 31 min was found between the time of onset of symptoms and start of thrombolytic infusion; and minor differences were found for systolic blood pressure, fibrinogen and fibrin degradation products. One patient in the PSH group had a previous infarction at the same location. In one patient in the HSH group, typical acute myocardial infarction symptoms were not confirmed. All other patients satisfied the inclusion criteria, and no patient had criterion for exclusion. In 114 patients (54 in the HSH group, 60 in the PSH group), myocardial infarction was confirmed electrocardiographically or enzymatically. A definite diagnosis was not available, in four patients. One patient in the PSH group died early and therefore did not undergo angiography. Ten patients (four in the HSH group, six in the PSH group) underwent coronary angiography after the 6-to 12-h time window. Therefore, 11 patients were classified as having occluded infarctrelated coronary arteries for the intention-to-treat analysis.
Angiographic findings. In 117 patients, coronary angiography was performed a mean of 8 h 22 rain (-+2 h 27 rain) after the initial heparin bolus in the HSH group and 8 h I min (+_2 h 27 min) after the initial placebo bolus in the PSH group. Perfusion (TIMI flow grade 2 or 3) was present in 83.9% of HSH group patients and 62.9% of PSH group patients. An intention-to-treat analysis resulted in patency rates of 78.6% in the HSH group and 56.5% in the PSH group (p = 0.01) ( Table  2 ). The initial time difference between onset of symptoms and start of therapy did not explain the difference in patency rates.
Clinical course. Between the end of catheterization and the end of hospital surveillance, 38 patier~ts underwent percutaneous transluminal coronary angioplasty and 5 coronary Tables 1 and 2. artery bypass graft surgery. The patency rates after angioplasty were 94.1% (HSH group) and 80.9% (PSH group). Ten patients received intracoronary thrombolysis with urokinase after angiography (Table 3 ). Bleeding events were reported for eight patients (14.3%) in the HSH group and five (8.1%) in the PSH group. Only one patient (HSH group) required transfusion because of a puncture site hemorrhage (Table 4 ). There was no marked difference between the two treatment groups with respect to incidence of recurrent infarction, arrhythmias, heart failure and angina pectoris at discharge. Definitive reinfarction occurred during the hospital phase in three patients (5.4%) in the HSH group and in six (9.7%) in the PSH group. No confirmed cerebrovascular event occurred in any of the 118 patients treated. Cerebral bleeding was suspected to be one of the possible causes of convulsion, circulatory collapse and subsequent death of one patient in the PSH group; however, the more likely cause of death was reinfarction or ventricular free wall rupture. An autopsy could not be performed. During the hospital phase there were three deaths (5.4%) in the HSH group and nine (14.5%) in the PSH gro,lp. The cause of death was cardiac related in 11 patients (heart failure) and unknown in 1 (PSH group). There was no suggestion or evidence of any allergic reaction occurring during the hospital phase in any of the patients treated.
Cardiac enzymes. The CK-MB peak concentrations and area under the curve were the same in both groups. However, the time to CK-MB peak concentration was shorter in the HSH group than in the PSH group (9 h 33 rain [+5 h 36 rain] vs. 10 h 39 rain [+-5 h 46 mini, respectively) ( Table 5) .
Coagulation and fibrinolytic analysis. There was a decline of fibrinogen concentrations as a result of thrombolytic therapy, which was similar in both treatment groups (median [25%, 75% percentile]): from 3.6 (2.8, 4.5) to 0.6 (0.1, 1.7) g/liter in the HSH group and from 3.1 (2.7, 4.0) to 0.9 (0.1,1.8) g/liter in the PSH group. As expected, the concentrations of fibdnogen and fibrin degredation products increased similarly in both groups. The median thrombin--antithromhin III complex values in the HSH group after lysis were lower than those in the PSH group (Table 6) .
Follow-up. Follow-up data were available for 103 patients at 1 year. Twelve patients died during the hospital phase and three during the 1-year follow-up period (cardiac-related events in two [PSH group], unknown events in one [HSH group]). The total mortality rate after 1 year was 12.7% (15 of 118 patients). In the HSH group, the total mortality rate after 1 year was 7.1% (4 of 56 patients), and that for the PSH group was 17.7% (11 of 62). The 1-year reinfarction rate after discharge was 1.9% for both groups. During the 1-year followup, five patients underwent bypass surgery and eight coronary angioplasty (four in each group). Health status according to Canadian Cardiovascular Society and functional classifications was similar in both groups after 1 year.
Discussion
The LIMITS study evaluated the 6-to 12-h patency of the infarct-related coronary artery rather than left ventricular function or survival, which are the ultimate goals of thrombo- lytic therapy after acute myocardial infarction, although the GUSTO (28) study shows that patency can be regarded as a valid end point and predictor of survival. The major finding of this double-blind trial was that treatment with heparin followed by saruplase led to higher coronary patency (78.6%) after 6 to 12 h, whereas treatment with placebo followed by saruplase resulted in a patency rate of only 56.5% (p = 0.01).
Conjunctive thrombolytic therapy. Current thrombolytic strategies in acute myocardial infarction have many shortcomings, including failure of recanalization within 90 min in 15% to 50% of patients (17); delay in the restoration of coronary flow (18) ; development of reocclusion in 5% to 15% of patients (7); and bleeding complications, especially intracranial bleeding, in up to 0.5% of patients (19) .
Conjunctive hepariu in mortality trials. The earliest study to evaluate hcparin as an adjunctive treatment to thrombolysis was the SCATI study (20) , in which throtrbolytic therapy with streptokinase was given within 6 h after onset of acute myocardial infarction. The mortality rate was significantly lower (4.5%) in patients randomly assigned to receive postlysis heparin (2,000 V intravenously, followed by 12,500 U subcutaneously every 12 h) compared with the control group (8.8%) with no heparin treatment after thrombolytic therapy. In the Data presented are median (25%; 75% percentile). Abbreviations as in Table 1, GISSI-2 international trials (21, 22) , the same trend was seen among patients who received both streptokinase and heparin (mortality rate was 7.9% vs. 9.2% for streptokinase alone). These data indicate that heparin given subcutaneously two times/day beginning 9 to 12 h after streptokinase therapy, with or without an intravenous bolus of heparin, is a useful adjuvant to str6ptokinase treatment in patients with an acute myocardial infarction (23) . In the ISIS-2 trial (24), patients were randomized to receive streptokinase or no thrombolysis. Heparin treatment was not part of the study protocol but was ased at the discretion of the physician and recorded. Patients with heparin (either subcutaneously or intravenously) in addition to streptokinase had a lower mortality rate (8.7%) than those without heparin (10.1%), but these results may be biased because there was no randomization. The ISIS-3 trial (25) randomized patients with suspected acute myocardial infarction, using a factorial design, to streptokinase, anistreplase or recombinant tissue-type plasminogen activator (rt-PA [duteplase]) and to receive 12,500 U of heparin two times/day subcutaneously, begun 4 h after lysis, or no heparin. All patients were to receive aspirin. During the heparin treatment period, up to day 7 there were slightly fewer deaths for aspirin plus heparin, but there was no significant difference in the 35-day mortality rate for aspirin plus heparin (10.3%) versus aspirin alone (10.6%) (26) . In the GISSI-2 international study group trial (21, 22) , the mortality rate among patients who received rt-PA and heparin (12,500 U subcutaneously twice daily, starting 12 h after lysis) was 9.2% and 8.7% among those who received rt-PA without heparin (p = 0.39). Finally, the addition of subcutaneous 5~parin to the thrombolytic regimens with streptokinase or rt-PA did not significantly reduce mortality compared with nonuse of heparin (27) . In the GUSTO trial (28) , there was no difference in mortality rates after streptokinase treatment with intravenous or subcutaneous heparin, b~t the accelerated rt-PA regimen combined with intravenous heparin (bolus dose of 5,000 U followed by a continuous infusion of 1,000 U/h) resulted in a 14% reduction in mortality rate to 6.3% compared with that after streptokinase. The accelerated rt-PA regimen with intravenous heparin also resulted in better patency rates (29) .
Conjunctive heparin in patency trials ( Table 7 ). The earliest randomized controlled study evaluating the additive effect of heparin on coronary patency is the Third Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-3) trial (30) , in which 134 patients with acute myocardial infarction of recent onset (<6 h) received rt-PA (1.5 mg/kg body weight over 4 h) with or without an intr:~venous bolus of 10,000 U heparin.
Coronary angiography was performed 90 min after start of therapy, a when the infusion of rt-PA is still in progress, and showed a pateney rate of 79% in both groups. It was concluded that early intravenous heparin does not facilitate the fibrinolyric effect of rt-PA, and heparin therapy can be delayed for at least 90 rain after the beginning of thrombolysis with rt-PA. In contrast, in a trial by Bleich et al. (31) , 84 patients were treated with 100 mg rt-PA for 3 h and were simultaneously randomized to receive intravenous heparin (bolus of 5,000 U, followed by 1,000 U/h for 3 days) or no heparin. Although coronary angiography was performed on day 3, the patency rate was significantly higher in the heparin (71%) than in the nonheparin group (43%). The Heparin Aspirin Reperfusion Trial (HART) (32,33) compared rt-PA plus heparin with rt-PA plus aspirin in ~200 patients. Patency measured by coronary angiography at a mean of 18 h after start of treatment was 82% in the heparin group and 52% in the aspirin group (p < 0.0001). In the Sixth European Coot~erative Study Group (ECSG-6) trial (34) , all patients received 100 mg of rt-PA and aspirin and were randomized to receive heparin or no heparin up to coronary angiography, which was performed between days 2 and 5. Patency (TIMI flow grade 2 and 3) was present in 83% of patients who had heparin therapy and in 75% of patients who did not (p -~ 0.02). The Duke University Clinical Cardiology Study (DUCCS-1) (35) was a randomized trial to evaluate the effects of heparin (15 U/kg per h, starting 4 h after lysis) in conjunction with anistreplase on coronary patency. A patent infarct-related artery (TIMI flow grade 2 or 3) was present in 80% of patients with and in 73% of those without heparin. At late, predischarge angiography on hospital day 5 the difference was not significant. In general, these studies show that early heparin therapy during the first hours after the start of thrombolytic therapy results in higher patency rates. It is possible that the effect of heparin is different for the various thrombolytic agents. In the present study, the only difference in postinfarction treatment was the prethrombolytic heparin bolus before saruplase. Whether the difference observed was due to the potentiaUon of action by saruplase or prevention of rethrombosis remains to be established. Howeve :, for alteplase the effect of heparin is more likely to be a reduction in the reocclusion rate (36) , and heparin may be replaced with an oral antiplatelet regimen 24 h after thrombolysis (37) .
Coagulation and fibrinolyde variables. The changes seen in fibrinogen and in fibrin and fibrinogen degradation products were as expected, and the initial bolus of heparin did not appear to exert an influence on their concentrations However, pretreatment with heparin may have prevented the increase in thrombin-aatithrombin III complex levels seen after saruplase therapy, possibly by preventing the positive feedback production by platelets stimulated during thrombolytic therapy or by inhibiting clot-localized thrombin activity reexposed by thrombolysis.
Bleeding complications. A moderate excess of bleeding was reported in the heparin group (14.3%) compared with that in the placebo group (8.1%), but only one severe bleeding event occurred in each group. Because there was no marked difference in the fibrinogen levels between the groups, this cannot be attributed to a possible increase in nonspecific lytic action by saruplase. There may have been an increase in the overall lytic efficacy caused by heparin cotreatment due to the attenuation of the opposing thrombotic activity of thrombin, as demonstrated by the reduced TAT III levels in the heparin group. This reasoning is not invalidated by the excess of mild bleeding events in the heparin group because these predominantly took place at puncture sites.
Limitations ~f the study. Antiplatelet drugs were not allowed during the first 5 days of the study. Higher patency rates, especially in the PSH group, might have been seen had these drugs been given. However, although mortality rate is lowered with aspirin (24), to our knowledge there has been no study to test the effect on patency rate. At the time of the design of the present study, the accepted definition of an open vessel was TIMI flow grade 2 or 3. A retrospective analysis of our data has shown that TIMI flow grade 3 was 75.0% (HSH group) and 59.6% (PSH group). Although the magnitude of the patency rate is diminished, the clinical impression remains the same. Patients in the HSH group were treated on average 31 rain earlier, and it may be assumed that this contributed to the difference in patency rates. The patency rate for those patients treated within 2 h in the HSH group was 86.4% versus 84.2% for those treated between 2 and 3 h. For the PSH group these were 50.0% and 66.7%, respectively. Therefore, although there is a difference with time, this does not appear to have played a major role in the result.
Clinical implications. The present study has important implications for the clinical use of saruplase because it shows that heparin given before the start of saruplase is necessary for improved efficacy (although there is a slight tendency toward more bleeding). Although the purpose of this pilot trial was not to recruit sufficient numbers of patients to demonstrate intergroup differences in mortality rate, the marked increase in the patency rate in the heparin group may have translated into the observed trend to a reduced in-hospital mortality rate (5.4% vs. 14.5% in the placebo group) (38) . On the basis of our findings that heparin pretreatment further improved the thrombolytic efficacy of saruplase without markedly increasing the incidence of severe adverse events, it must now be strongly urged that saruplase treatr,ent always be preceded by a heparin bolus (5,000 ILl ii,,ravenously).
